Hunan Cancer Hospital
🇨🇳China
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
Phase 3
Recruiting
- Conditions
- Non Small Cell Lung CancerSmall Cell Lung Cancer
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 121
- Registration Number
- NCT06840704
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
Phase 2
Recruiting
- Conditions
- Nasopharyngeal Cancinoma (NPC)
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT06788002
- Locations
- 🇨🇳
Huai Liu, Changsha, Hunan, China
🇨🇳Hui Wang, Changsha, Hunan, China
Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC
Phase 2
Recruiting
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06752798
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
Active, not recruiting
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT06748495
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
Recruiting
- Conditions
- HR+ Breast Cancer
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06734533
- Locations
- 🇨🇳
Hunan Provincial Tumor Hospital, Changsha, Hunan, China
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
Recruiting
- Conditions
- CancerFAP
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT06557590
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
Recruiting
- Conditions
- Gastric Cancer
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06543108
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer
Not Applicable
Not yet recruiting
- Conditions
- Advanced Gastric Cancer
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06486545
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06406634
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT06385990
- Locations
- 🇨🇳
Quchang Ouyang, Changsha, Hunan, China
© Copyright 2025. All Rights Reserved by MedPath